Exact Sciences Acquires PreventionGenetics

Exact Sciences Acquires Thrive Earlier Detection

October 27, 2020

Healthcare Services

Exact Sciences Corp. agreed to acquire Thrive Earlier Detection Corp. for up to $2.15 billion in cash and stock, a deal intended to combine Thrive's CancerSEEK multi-cancer blood test with Exact Sciences' commercial and R&D capabilities. The transaction, unanimously approved by both boards, is designed to accelerate development, regulatory approval, and adoption of blood-based multi-cancer screening.

Exact Sciences Acquires Paradigm Diagnostics and Viomics

March 3, 2020

Healthcare Services

Exact Sciences Corp. has completed the acquisitions of Phoenix-based Paradigm Diagnostics, Inc. and Viomics, Inc., adding a late-stage therapy selection genomic profiling test, a scalable clinical lab, and sequencing/biomarker discovery capabilities to its precision oncology portfolio. The deals (financial terms largely undisclosed in the company release) bring Paradigm and Viomics into Exact Sciences’ research and commercial platform to accelerate tissue- and blood-based advanced cancer diagnostics.

Praesidian Capital Acquires Undisclosed Genetics Business

September 18, 2019

Healthcare Services

Praesidian Capital announced the acquisition of an integrated clinical and laboratory services company operating in genetic medicine, focused on prenatal and preconception testing and hereditary cancer risk assessments. The deal is Praesidian’s first as an independent sponsor and will serve as a platform for national expansion and future add-on acquisitions.

Tesis Biosciences Acquires Genome Explorations

February 16, 2022

Biotechnology

Tesis Biosciences has acquired Genome Explorations to accelerate its clinical research and product development efforts in targeted genetic sequencing and precision medicine. The acquisition brings Genome Explorations’ genomic profiling and molecular diagnostics capabilities and clinical research staff into Tesis’ integrated platform to speed development of proprietary therapeutics and diagnostic products.

OncoCyte Corporation Acquires Insight Genetics

January 10, 2020

Healthcare Services

OncoCyte Corporation agreed to acquire all outstanding capital stock of Insight Genetics, a privately held molecular diagnostics company, for approximately $12 million in cash and stock plus potential contingent payments. The acquisition adds Insight Genetics' IM Score immuno-oncology diagnostic test and a pharma-trial–capable CLIA/CAP lab to OncoCyte's portfolio to expand its capabilities in oncology diagnostics and pharma services.

Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business

July 15, 2019

Healthcare Services

Interpace Diagnostics Group, Inc. acquired assets and certain liabilities comprising the Biopharma Services business of Cancer Genetics, Inc. for approximately $23.5 million, with the business continuing to operate from labs in Rutherford, New Jersey and Research Triangle Park, North Carolina. In conjunction with the transaction Ampersand Capital Partners invested $27 million in Interpace via convertible preferred stock to support the acquisition and Interpace’s growth in the clinical diagnostic and biopharma services markets.